The other two leading manufacturers — GlaxoSmithKline and Teva — have not agreed to a price cap. The lawmakers have pointed to sizable differences in inhaler co-pays between the United States ...

(The Hill) — Drugmaker Boehringer Ingelheim plans to cap the out-of-pocket costs for all its inhalers at $35 a month after coming under fire from Democratic lawmakers over pricing. The company ...